Dupixent

Active substance

Dupilumab

Holder

Sanofi Belgium

Status

Running

Indication

Treatment of moderate-to-severe atopic dermatitis in adult patients coming from the Open Label Extension study (OLE)R668-AD-1225 and who are candidates for systemic therapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

09/05/2019